A Study of Pembrolizumab in People With Ultra-Rare Sarcomas (NCT07089992)

🧪 Interventions in This Study

• Pembrolizumab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must have pathologically confirmed diagnosis of one of the following:
2. Pleomorphic liposarcoma
3. PEComa (perivascular epithelial cell tumor)
4. Epithelioid sarcoma
5. CIC-rearranged sarcoma
6. SEF/LGFMS: Sclerosing epithelioid fibrosarcoma - low grade fibromyxoid sarcoma
7. Molecular characterization of the tumor, if available, will be recorded. If no such molecular data are available, note as such.
8. Patient should have recurrent or metastatic disease not judged to be curable with other means
9. Patients must have progressed (in the opinion of the treating investigator) following the most recent line of therapy or stop prior therapy due to toxicity or patient choice. The reason for this progression or other reason for changing therapy must be documented, employing tumor measurements when available.
10. Definition of Measurable Disease
11. Measurable disease as per RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions for a minimum of 3 months after completion of such therapy
12. Patients with treated brain metastases are eligible if follow up brain imaging after CNS-directed therapy shows no evidence of progression at least 4 weeks after the completion of therapy as shown by follow up imaging before study screening

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (7 Sites)

• Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
• Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
• Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) — Commack, New York
• Memorial Sloan Kettering at Westchester (Limited Protocol Activities) — Harrison, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
• Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York

📞 Contact the Study Coordinator

Phone: (646) 888-5059

Email: zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Sarcoma

• Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study — Durham, North Carolina
• Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma — Milwaukee, Wisconsin
• Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor — New York, New York
• Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma — Houston, Texas
• Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® — Philadelphia, Pennsylvania

Explore by condition: All Sarcoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.